In metastatic breast cancer, resistance to therapy remains one of the most challenging aspects to care. A key driver of resistance in hormone receptor-positive, HER2-negative disease is the ESR1 mutation, a genetic change that alters the estrogen receptor and limits the effectiveness of certain standard therapies. In this episode, CANCER BUZZ speaks with Eleonara Teplinsky, MD, FASCO, head of breast and gynecologic medical oncology at Valley-Mount Sinai Comprehensive Cancer Care, about how the ESR1 mutation shapes treatment decisions and explains communication strategies, such as the "lock-and-key" model. Then CANCER BUZZ speaks with Maimah Karmo, president and CEO of Tigerlily Foundation about the importance of communicating with patients in ways that foster clarity and compassion through relatable analogies.
Guest:
Eleonora Teplinsky, MD, FASCO
Medical Oncologist
Valley Mount Sinai Comprehensive Cancer Care
Paramus, NJ
Maimah Karmo
President/CEO
Tigerlily Foundation
"If you had molecular testing of your tumor done at the time of diagnosis, that may not be enough. If there is disease progression, we might need to repeat it. So it's really important to stress that there are points in the disease course where we're going to be checking for these biomarkers." - Teplinsky
"The more that we can know about the tumor, how it's going to behave, what treatment it may or may not respond to, really can help us." - Teplinsky
"Having a physician that is a true partner with the patient, that has a relationship, that's trusted, and that feels safe and secure, it's really, really critical." - Karmo
Resources:
Unlocking the Conversation: Navigating ESR1 Mutations in Metastatic Breast Cancer
